login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Fluoroscopy times and radiation exposure during renal denervation compared to coronary procedures


Thursday, 15 Mar 2012 10:36

A retrospective analysis conducted in Germany shows that fluoroscopy times and radiation exposure in patients undergoing renal denervation are similar to those in patients undergoing routine diagnostic catheterisation with elective percutaneous coronary intervention but lower than in patients undergoing emergency intervention. The results were showed in a poster presentation at ISET in Miami, USA.


Ionising radiation carries an oncogenic risk which is linearly related to the dose and is closely related to procedural time. An estimation of the effective dose can be obtained from the measurements of the dose-area product, which is a measure of stochastic risk and a potential quality indicator,” the authors, led by Frank Himmel, Medizinische Klinik II, Universitätsklinikum Schleswig-Holstein, Lübeck, wrote.


The aim of the study was to assess fluoroscopy time, radiation exposure (dose area-product) and contrast dye consumption in patients undergoing renal denervation to treat medically resistant hypertension in comparison to diagnostic catheterisation and percutaneous coronary intervention.


A retrospective analysis of renal denervation therapy and adult cardiac percutaneous procedures (consecutive patients between January to May 2011 undergoing coronary angiography and ventriculography) was carried out to determine procedural characteristics and the dose-area product. The investigators identified four groups: group 1 (n=790, coronary angiography); group 2 (n=141, elective percutaneous coronary intervention in stable patients); group 3 (n=160, emergency percutaneous coronary intervention in acute coronary syndrome patients), group 4 (n=54, patients undergoing renal denervation). Dose-area product meter attached to the X-ray unit was used for the estimation of the radiation dose received by the patient during the procedures. In average renal denervation therapy consisted of 6–9 bilateral ablations spots.


The results showed that in the renal denervation group fluoroscopy time, dose-area product and contrast dye consumption were 10±1sec, 4878±456cGy cm2 and 141±6mL, respectively. In the elective percutaneous coronary intervention, fluoroscopy time was 11±1sec, dose-area product was 7457±421cGy cm2, and contrast dye consumption was 136±5mL. In emergency percutaneous coronary intervention patients, fluoroscopy time was 12±1sec, dose-area product was 9046±482cGy cm2, and contrast dye consumption was 213±6±5mL.


The authors concluded that the radiation dose varies substantially across different types of procedures and up to tenfold within the same procedure. “The enhanced knowledge of radiation dose might help the cardiologist to implement radiation sparing procedures minimising patient and operator radiation hazards in renal denervation,” they wrote.

 

 

Results (mean±standard error of the mean)

Body weight (kg)

Fluoroscopy time (sec)

Dose-area product (cGy cm2)

CDC (mL)

Group 1 (coronary angiography)

82±1

5±0.6

3514±99

99±1

Group 2 (elective PCI)

84±1

11±1*

7457±421*

136±5*

Group 3 (emergency PCI)

82±1

12±1*

9046±482*+

213±6*+

Group 4 (renal denervation)

92±3*

10±1*

4878±456*

141±6*

 

* p<0.05 vs. group 1, + p<0.05 vs. group 2




Add New Comment

Related Items


Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

French hospital celebrates 30 years of implanting artificial hearts
Wednesday, 13 Apr 2016
La Pitié-Salpêtrière Hospital (Paris, France), the world’s leading artificial heart centre, is celebrating the 30th anniversary of the first Total Artificial Heart implantation. The centre has now ... French hospital celebrates 30 years of implanting artificial hearts

Tuesday, 05 Apr 2016
One-month, follow-up patient cohort data from the Revelution trial of Medtronic’s novel drug-filled stent indicate that device is associated with rapid vessel healing without inflammation, as ... Early data show good rapid healing for Medtronic’s investigational drug-filled stent

Features


Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy
Monday, 09 May 2016
According to Usman Baber, TWILIGHT is a unique and innovative study in that the experimental intervention is to withdraw rather than add to existing background pharmacotherapy. In this commentary, he ... Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy

The role of sutureless and rapid-deployment valves
Tuesday, 05 Apr 2016
Antonio Miceli explores the data for sutureless and rapid-deployment surgical valves for the management of patients with severe aortic stenosis. He also reviews the place of these new devices ... The role of sutureless and rapid-deployment valves

Profiles


Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions